Anna S. Sedukhina, Elayanambi Sundaramoorthy, Masaki Hara, T. Kumai, Ko Sato
{"title":"超越对PARP抑制的抵抗:机制和有效的治疗选择。","authors":"Anna S. Sedukhina, Elayanambi Sundaramoorthy, Masaki Hara, T. Kumai, Ko Sato","doi":"10.14800/CCM.821","DOIUrl":null,"url":null,"abstract":"Poly-ADP ribosylation polymerase (PARP) inhibition is a promising new strategy that specifically kills malignancies with mutation of BRCA genes. However, as in other agents, it is known that continuous treatment with PARP inhibitors generates acquired resistance in these tumors. In this review, we discuss about the potential mechanisms of acquired resistance to the PARP inhibition that is routed through up-regulation of the NF-κB signaling pathway and furthermore discuss about potential treatment options for malignancies that gain such resistance.","PeriodicalId":9576,"journal":{"name":"Cancer cell & microenvironment","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Beyond resistance to PARP inhibition: Mechanisms and effective treatment options.\",\"authors\":\"Anna S. Sedukhina, Elayanambi Sundaramoorthy, Masaki Hara, T. Kumai, Ko Sato\",\"doi\":\"10.14800/CCM.821\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Poly-ADP ribosylation polymerase (PARP) inhibition is a promising new strategy that specifically kills malignancies with mutation of BRCA genes. However, as in other agents, it is known that continuous treatment with PARP inhibitors generates acquired resistance in these tumors. In this review, we discuss about the potential mechanisms of acquired resistance to the PARP inhibition that is routed through up-regulation of the NF-κB signaling pathway and furthermore discuss about potential treatment options for malignancies that gain such resistance.\",\"PeriodicalId\":9576,\"journal\":{\"name\":\"Cancer cell & microenvironment\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-05-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer cell & microenvironment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14800/CCM.821\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer cell & microenvironment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14800/CCM.821","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Beyond resistance to PARP inhibition: Mechanisms and effective treatment options.
Poly-ADP ribosylation polymerase (PARP) inhibition is a promising new strategy that specifically kills malignancies with mutation of BRCA genes. However, as in other agents, it is known that continuous treatment with PARP inhibitors generates acquired resistance in these tumors. In this review, we discuss about the potential mechanisms of acquired resistance to the PARP inhibition that is routed through up-regulation of the NF-κB signaling pathway and furthermore discuss about potential treatment options for malignancies that gain such resistance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
